Cargando…

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study

BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Musa, Ahmed M., Younis, Brima, Fadlalla, Ahmed, Royce, Catherine, Balasegaram, Manica, Wasunna, Monique, Hailu, Asrat, Edwards, Tansy, Omollo, Raymond, Mudawi, Mahmoud, Kokwaro, Gilbert, El-Hassan, Ahmed, Khalil, Eltahir
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964291/
https://www.ncbi.nlm.nih.gov/pubmed/21049063
http://dx.doi.org/10.1371/journal.pntd.0000855
_version_ 1782189348799643648
author Musa, Ahmed M.
Younis, Brima
Fadlalla, Ahmed
Royce, Catherine
Balasegaram, Manica
Wasunna, Monique
Hailu, Asrat
Edwards, Tansy
Omollo, Raymond
Mudawi, Mahmoud
Kokwaro, Gilbert
El-Hassan, Ahmed
Khalil, Eltahir
author_facet Musa, Ahmed M.
Younis, Brima
Fadlalla, Ahmed
Royce, Catherine
Balasegaram, Manica
Wasunna, Monique
Hailu, Asrat
Edwards, Tansy
Omollo, Raymond
Mudawi, Mahmoud
Kokwaro, Gilbert
El-Hassan, Ahmed
Khalil, Eltahir
author_sort Musa, Ahmed M.
collection PubMed
description BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days. METHODS: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment regimens. Patients with clinical features and positive bone-marrow aspirates for VL were enrolled. All patients received their assigned courses of PM intramuscularly and adverse events were monitored. Parasite clearance in bone-marrow aspirates was tested by microscopy at end of treatment (EOT, primary efficacy endpoint), 3 months (in patients who were not clinically well) and 6 months after EOT (secondary efficacy endpoint). Pharmacokinetic data were obtained from a subset of patients weighing over 30 kg. FINDINGS: 42 patients (21 per group) aged between 4 and 60 years were enrolled. At EOT, 85% of patients (95% confidence interval [CI]: 63.7% to 97.0%) in the 20 mg/kg/day group and 90% of patients (95% CI: 69.6% to 98.8%) in the 15 mg/kg/day group had parasite clearance. Six months after treatment, efficacy was 80.0% (95% CI: 56.3% to 94.3%) and 81.0% (95% CI: 58.1% to 94.6%) in the 20 mg/kg/day and 15 mg/kg/day groups, respectively. There were no serious adverse events. Pharmacokinetic profiles suggested a difference between the two doses, although numbers of patients recruited were too few to make it significant (n = 3 and n = 6 in the 20 mg/kg/day and 15 mg/kg/day groups, respectively). CONCLUSION: Data suggest that both high dose regimens were more efficacious than the standard 15 mg/kg/day PM for 21 days and could be further evaluated in phase III studies in East Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00255567
format Text
id pubmed-2964291
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29642912010-11-03 Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study Musa, Ahmed M. Younis, Brima Fadlalla, Ahmed Royce, Catherine Balasegaram, Manica Wasunna, Monique Hailu, Asrat Edwards, Tansy Omollo, Raymond Mudawi, Mahmoud Kokwaro, Gilbert El-Hassan, Ahmed Khalil, Eltahir PLoS Negl Trop Dis Research Article BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days. METHODS: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment regimens. Patients with clinical features and positive bone-marrow aspirates for VL were enrolled. All patients received their assigned courses of PM intramuscularly and adverse events were monitored. Parasite clearance in bone-marrow aspirates was tested by microscopy at end of treatment (EOT, primary efficacy endpoint), 3 months (in patients who were not clinically well) and 6 months after EOT (secondary efficacy endpoint). Pharmacokinetic data were obtained from a subset of patients weighing over 30 kg. FINDINGS: 42 patients (21 per group) aged between 4 and 60 years were enrolled. At EOT, 85% of patients (95% confidence interval [CI]: 63.7% to 97.0%) in the 20 mg/kg/day group and 90% of patients (95% CI: 69.6% to 98.8%) in the 15 mg/kg/day group had parasite clearance. Six months after treatment, efficacy was 80.0% (95% CI: 56.3% to 94.3%) and 81.0% (95% CI: 58.1% to 94.6%) in the 20 mg/kg/day and 15 mg/kg/day groups, respectively. There were no serious adverse events. Pharmacokinetic profiles suggested a difference between the two doses, although numbers of patients recruited were too few to make it significant (n = 3 and n = 6 in the 20 mg/kg/day and 15 mg/kg/day groups, respectively). CONCLUSION: Data suggest that both high dose regimens were more efficacious than the standard 15 mg/kg/day PM for 21 days and could be further evaluated in phase III studies in East Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00255567 Public Library of Science 2010-10-26 /pmc/articles/PMC2964291/ /pubmed/21049063 http://dx.doi.org/10.1371/journal.pntd.0000855 Text en Musa et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Musa, Ahmed M.
Younis, Brima
Fadlalla, Ahmed
Royce, Catherine
Balasegaram, Manica
Wasunna, Monique
Hailu, Asrat
Edwards, Tansy
Omollo, Raymond
Mudawi, Mahmoud
Kokwaro, Gilbert
El-Hassan, Ahmed
Khalil, Eltahir
Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
title Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
title_full Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
title_fullStr Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
title_full_unstemmed Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
title_short Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
title_sort paromomycin for the treatment of visceral leishmaniasis in sudan: a randomized, open-label, dose-finding study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964291/
https://www.ncbi.nlm.nih.gov/pubmed/21049063
http://dx.doi.org/10.1371/journal.pntd.0000855
work_keys_str_mv AT musaahmedm paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT younisbrima paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT fadlallaahmed paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT roycecatherine paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT balasegarammanica paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT wasunnamonique paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT hailuasrat paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT edwardstansy paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT omolloraymond paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT mudawimahmoud paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT kokwarogilbert paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT elhassanahmed paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy
AT khalileltahir paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy